The review panel shall examine the following areas relating to fungal contamination in indoor environments:
(a) Medical and public health.
(b) Evaluation and monitoring.
(c) Remediation and prevention.
(d) Educational materials.
(e) Hazard communication.
(f) Any other area identified by the review panel.